Nicolas Chahine

By Nicolas Chahine, InvestorPlace Contributor Jan 14, 2022

Clover Health has a billion dollar yearly book of sales. Selloffs have limits, and we will soon find out if CLOV stock is a dud or a stud.

By Nicolas Chahine, InvestorPlace Contributor Jan 13, 2022

The biotech sector is prone to surprise headlines. But these biotech stocks to buy today have had fallen so much that they hit bottom.

By Nicolas Chahine, InvestorPlace Contributor Jan 12, 2022

Cloudflare positioned itself well for the long term. So NET stock 50% correction is an opportunity for new investors but not all in.

By Nicolas Chahine, InvestorPlace Contributor Jan 11, 2022

BABA stock is inherently pretty risky, but there's reason to believe it could grow from here. $140 will be a crucial point in its ascent.

By Nicolas Chahine, InvestorPlace Contributor Jan 10, 2022

T stock has reached a stage in its chart that can best be described as "so bad it's good." It's a good time to enter a position with AT&T.

By Nicolas Chahine, InvestorPlace Contributor Jan 10, 2022

Here are 3 ugly charts of great stocks to buy on dips. Investor sentiment is largely to blame, so there will be buyers lurking below.

By Nicolas Chahine, InvestorPlace Contributor Jan 7, 2022

DocuSign management caused its own drama last year. Now DOCU stock is on a mission to build a base for its 2022 recovery.

By Nicolas Chahine, InvestorPlace Contributor Jan 6, 2022

TWTR stock rose 300% since its pandemic lows, so it shouldn't be surprising or worrying that it has since given up some of those gains.

By Nicolas Chahine, InvestorPlace Contributor Jan 6, 2022

Markets are near highs but the bargain bins are full of great stocks to buy on dips. ROKU, CRM and PLTR are three to consider this year.

By Nicolas Chahine, InvestorPlace Contributor Jan 5, 2022

CHPT stock is starting off 2022 from a position of strength. Investors at these levels have more conviction than at the start of 2021.

Recent Articles